Shield Therapeutics is a well-funded, high potential, commercial stage specialty-pharma company. We pride ourselves on providing solutions to unmet medical needs and delivering value to our shareholders.
Shield has a rare opportunity to build an integrated, highly profitable specialty pharma business. In this section you can learn more about our lead product, and about our second asset.
Shield is well positioned to become a fast growing, independent, international specialty pharmaceutical company due to the strength of its products and team, and with great thanks to all of our supportive shareholders.
Stay up to date with the exciting new developments as we continue to grow.
Shield Therapeutics plc, announces that the following documents have been sent to shareholders: · Annual Report and Accounts for the year ended 31 December 2018…
Shield Therapeutics plc, announces that the Swiss Agency for Therapeutic Products (Swissmedic) has approved a major extension of the approved indication for Feraccru® to now…
Shield Therapeutics plc, announces its preliminary Group results for the year ended 31 December 2018. For full details click here.
Shield Therapeutics plc, announces the appointment of Peel Hunt LLP as its Nominated Adviser with immediate effect. Peel Hunt will continue to act as broker…
Shield Therapeutics plc, will be announcing its final results for the financial year ended 31 December 2018 on Wednesday 3 April 2019. Analyst briefing A…
Shield Therapeutics plc, announces that, further to the announcement on 24 January 2019 and in relation to the Group’s patent #2 668 175, which…
Shield Therapeutics plc, announces positive results from the AEGIS-H2H clinical trial which compared Feraccru® (ferric maltol), a novel oral iron replacement therapy, to Ferinject® (ferric…
Shield Therapeutics plc, announces positive results from the open-label extension phase of the AEGIS-CKD pivotal study of Feraccru®, a novel oral ferric iron therapy that…
Shield Therapeutics plc, today provides a business and unaudited trading update for the year ended 31 December 2018. For further details and to view the…
